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Background: Sinobronchial syndrome is a cause of chronic productive cough. Inflammatory mediators are
involved in the pathophysiology of chronic productive cough. Accumulating evidences indicate that
cyclooxygenase (COX)-2, one of the inducible isoforms of COX, is a key element in the pathophysiological process
of a number of inflammatory disorders. However, little is known about the role of COX-2 in chronic productive
cough in patients with sinobronchial syndrome known as neutrophilic bronchial inflammation.
Methods: The effect of etodolac, a potent COX-2 inhibitor, on cough response to inhaled capsaicin was examined
in 15 patients with sinobronchial syndrome in a randomized, placebo-controlled cross-over study. Capsaicin cough
threshold, defined as the lowest concentration of capsaicin eliciting five or more coughs, was measured as an
index of airway cough reflex sensitivity.
Results: The cough threshold was significantly (p < 0.03) increased after two-week treatment with etodolac (200
mg twice a day orally) compared with placebo [37.5 (GSEM 1.3) vs. 27.2 (GSEM 1.3) μM].
Conclusions: These findings indicate that COX-2 may be a possible modulator augmenting airway cough reflex
sensitivity in patients with sinobronchial syndrome.
Background
C h r o n i cp r o d u c t i v ec o u g hi so n eo ft h em o s tc o m m o n
symptoms in patients with sinobronchial syndrome, a
common chronic bronchial disorder, which is defined as
a coexisting chronic sinusitis and nonspecific chronic
neutrophilic inflammation of the lower airways present-
ing with expectoration (e.g. chronic bronchitis, diffuse
bronchiectasis and diffuse panbronchiolitis [1]).
Although clinical efficacy for low-dose and long-term
erythromycin therapy (EM therapy) has been established
in patients with sinobronchial syndrome [2,3], our pre-
vious study has shown that 3-6 months are required to
improve the cough, sputum and other symptoms [3]. So,
it is important to clarify the mechanisms of chronic pro-
ductive cough to improve social activity in patients suf-
fering sinobronchial syndrome. Previous studies [2-5]
implied the involvement of inflammatory mediators in
sinobronchial syndrome, however, exact mechanisms
underlying cough in this disorder has been remained
obscure [3].
Cyclooxygenase (COX) is an essential enzyme in the
pathway of prostaglandin formation from arachidonic
acid. The previous studies [6,7] have revealed the exis-
tence of two isoforms of COX, namely COX-1 and
COX-2, with similar molecular weights. COX-1 is a con-
stituent of healthy cells and is expressed under normal
conditions. On the other hand, COX-2 is highly induci-
ble by a number of stimuli including cytokines and is
associated with inflammation. It has been suggested that
the induction and regulation of COX-2 may be key ele-
ments in the pathophysiological process of a number of
inflammation [8]. These findings imply the role of
COX-2 in controlling cough reflex sensitivity in sino-
bronchial syndrome, because cough is one of the major
symptoms in this disorder. Our previous study showed
that non-specific COX inhibitor, indomethacin, could
modulate airway cough reflex sensitivity to inhaled cap-
saicin [9]. Therefore, we conducted this study in patients
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a potent COX-2 inhibitor [10,11].
Methods
Subjects
Fifteen patients with stable sinobronchial syndrome
(5 males and 10 females) with a mean age of 71.6 ± 1.3
(± SEM) (range 55-79) yrs participated in this study. All
patients were lifetime nonsmokers or ex-smokers with-
out exceeding 10 pack-years to exclude patient with
COPD or smoking-induced bronchitis and with no his-
tory of viral infection for at least 4 weeks prior to the
study. Informed consent was obtained from all subjects.
This study was approved by the Ethics Committee of
our hospital.
Sinobronchial syndrome is a common chronic bron-
chial disorder in Japan, which is not related to smoking.
We provide some details, as it is not recognized as a
diagnostic category by the ATS. Sinobronchial syndrome
is defined as a coexisting chronic sinusitis and nonspeci-
fic chronic neutrophilic inflammation of the lower air-
ways presenting with expectoration (e.g. chronic
bronchitis, diffuse bronchiectasis and diffuse panbronch-
iolitis [1]). Suzaki et al. [12] reported that the sinobron-
chial syndrome was found in 10% of 309 patients with
chronic sinusitis and in 55% of 74 patients with chronic
lower respiratory tract infectious diseases. They sug-
gested that there is a gene controlling the susceptibility
to sinobronchial syndrome, especially diffuse pan-
bronchiolitis, which is significantly associated with
human leukocyte antigen (HLA)-BW54; this is found
specifically in Japanese and not in Caucasians. The
obstructive form of sinobronchial syndrome is known as
“diffuse panbronchiolitis” [1].
Recognition of the sinobronchial syndrome is very
important in Japan because long-term, low dose erythro-
mycin therapy is specifically effective [2,3], as inhaled
steroid therapy for bronchial asthma. In our patients,
diagnosis of the sinobronchial syndrome was based on
the following criteria: 1) productive cough on most days
for at least 3 months for 2 consecutive years, 2) chronic
sinusitis diagnosed based on symptoms (postnasal drip,
nasal discharge and nasal obstruction), physical exami-
nations and plain roentgenogram as indicated by opaci-
ties or air-fluid levels of one or more paranasal sinuses,
3) no history suggesting to the attending physician that
they had bronchial asthma, 4) no history of wheezing
syndrome, and 5) no significant emphysema documen-
ted by chest computed tomographic scan.
Each studied patient did not have perennial or vaso-
motor rhinitis. They were taking low-dose erythromycin
and mucolytic agents, such as carbocysteine and
ambroxol, however, not theophylline, b2-adrenoceptor
stimulants, or glucocorticosteroids. This study was car-
ried out when their symptoms were mild and stable.
Assessment of cough reflex sensitivity to inhaled
capsaicin
Cough receptor sensitivity was assessed by capsaicin
provocation test [13]. Capsaicin (30.5 mg) was dissolved
in Tween 80 (1 mL) and ethanol (1 mL) and then dis-
solved in physiological saline (8 mL) to make a stock
solution of 1 × 10-2 M, which was stored at -20°C.
This solution was diluted with physiological saline to
make solutions starting at a concentration of 0.49 μM
and increasing it by doubling concentrations up to 1000
μM. Each subject inhaled a control solution of physiolo-
gical saline followed by progressively increasing concen-
trations of the capsaicin solution. Solutions were inhaled
for 15 s every 60 s, by tidal mouth-breathing wearing a
noseclip from a Bennett Twin nebulizer (3012-60cc,
Puritan-Bennett Co., Carlsbad, California, USA). Increas-
ing concentrations were inhaled until five or more
coughs were elicited. The nebulizer output was 0.21
mL/min. The number of capsaicin-induced coughs was
counted by a blinded medical technician in our pulmon-
ary function laboratory. The cough threshold was
defined as the lowest concentration of capsaicin that eli-
cited five or more coughs.
Study protocol
The concomitant medication was stopped at 9.00 p.m.
on the previous day to allow a washout time of 12 h or
more before the measurement of cough threshold to
inhaled capsaicin at 10.00 a.m. on each test day.
Each patient attended 4 times separated by 2 weeks, at
the same time each day. Control measurement of cap-
saicin cough threshold was carried out before the first
treatment. After two weeks as wash out period, treat-
ment with etodolac and placebo was performed in a
randomized, cross-over fashion, putting a washout per-
iod of 2 weeks between the treatments. Etodolac tablet
(200 mg) or its placebo was taken orally twice a day for
14 days and at 8.00 a.m. on the test day. FEV1 was mea-
sured on a dry wedge spirometer (Chestac 11, Chest
Co., Ltd., Tokyo, Japan) before capsaicin challenge to
assess the bronchoactive effect of the treatment
regimens.
Data analysis
Capsaicin cough threshold values were expressed as geo-
metric mean with geometric standard error of the mean
(GSEM). Forced vital capacity (FVC) and FEV1 were
shown as arithmetic mean values ± SEM. The cough
threshold, the FVC and the FEV1 values were compared
between each pair of the four test periods (run-in,
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the Wilcoxon signed-ranks test. Data are transformed to
logarithmic values for cough threshold at this test. A
p-value of less than 0.05 was taken as significant.
Results
Cough threshold to inhaled capsaicin before each treat-
ment (run-in and washout period) and after treatment
with etodolac and placebo are shown in figure 1. Geo-
metric mean values for the cough threshold were 25.9
(GSEM 1.4) μM in run-in period, 25.9 (GSEM 1.4) μM
in washout period, 27.2 (GSEM 1.3) μM after placebo
treatment and 37.5 (GSEM 1.3) μM after etodolac treat-
ment. The cough threshold after the etodolac treatment
was significantly greater than the value after run-in per-
iod, wash out period and the placebo treatment (p <
0.03). FVC or FEV1 value was not significantly different
among run-in period, washout period, etodolac treat-
ment and placebo treatment as shown in the table 1.
Sputum cells were counted in seven patients and
observed increasement of neutrophils (40-94%, mean
67.7%). CT scan was not conducted in this study, abnor-
mal finding in sinus Xp were observed in every patients.
After the administration of etodolac, none of the
patients enrolled in this study complained of cardiovas-
cular or gastroenterological symptoms which have been
reported for other COX-2 inhibitors, such as rofecoxib,
celecoxib and valdecoxib [14,15].
Discussion
The present study showed that two-week treatment with
a potent COX-2 inhibitor, etodolac, increased the cough
threshold to inhaled capsaic i ni ns t a b l ep a t i e n t sw i t h
sinobronchial syndrome. No difference could be found
in the baseline pulmonary function between etodolac
and placebo treatments. From these findings, COX-2
may be a possible modulator augmenting airway cough
reflex sensitivity in bronchitic airway.
Though cough is an important protective mechanism
for the cleaning of the excessive mucus production [16],
chronic cough can be a difficult clinical problem for
physicians interfering with patient’s quality of life
through loss of sleep, interruption of work and social
embarrassment. However, mechanism correlating to the
cough reflex sensitivity in sinobronchial syndrome
remains unclear.
Previous investigators demonstrated the efficacy of EM
therapy for chronic bronchitic disorders; sinobronchial
syndrome and diffuse panbronchiolitis, which is recog-
nized as a severe obstructive form of sinobronchial syn-
drome [2,3]. EM therapy has excellent effect through
the improvement of pulmonary inflammation by redu-
cing the intrapulmonary chemotactic gradient or the
ability of the neutrophils to respond to chemotactic fac-
tors, ultimately reducing the migration of neutrophils to
inflammatory sites [2,3,17], but at least eight weeks are
required to improve the symptoms including chronic
productive cough [2,3]. We also failed to improve cough
reflex sensitivity to inhaled capsaicin by four-week treat-
ment of clarithromycin, another form of long term ther-
apy for this disorder [18]. Thus it is important to clarify
the potential mechanisms of chronic productive cough
in patients suffering from sinobronchial syndrome to
improve their symptoms more early.
C O Xi st h ek e ye n z y m ei nt h ep a t h w a yo fp r o s t a -
glandin formation consisting of at least two isoforms,
namely COX-1 and COX-2 [6,7]. COX-1 is constitu-
tively expressed in most tissues, and maintains home-
ostasis of various physiologic functions. COX-2 is, with
some exceptions, not generally found in healthy tis-
sues, but its expression is markedly induced in inflam-
mation. It can be induced by various stimuli, including
inflammatory cytokines, resulting in further production
of inflammatory substances such as prostanoids [6,7].
Previous study suggested that the induction and regu-
lation of COX-2 may be key elements in the pathophy-











































Placebo Etodolac Run-in Wash out
Figure 1 Individual data of capsaicin cough threshold before
each treatment and after placebo and etodolac treatments in
patients with chronic bronchitis. Each horizontal bar represents
geometric mean value. * P < 0.03: an one-way analysis of variance
using logarithmically transformed values.
Table 1 Pulmonary functions on etodolac and placebo
treatments in patients with sinobronchial syndrome
Run-in Placebo Wash out Etodolac
FVCs as % pred.
(%)
106.7 ± 4.3 108.8 ± 4.1 106.6 ± 4.4 112.5 ± 1.2
FEV1 s as % pred.
(%)
119.3 ± 5.1 118.8 ± 6.1 116.5 ± 9.1 112.0 ± 9.0
FEV1/FVC ratio as
% pred. (%)
76.6 ± 6.0 74.6 ± 7.0 76.3 ± 6.4 72.5 ± 5.4
Data are shown as mean ± standard error of the mean for FVC, FEV1 and
FEV1/FVC ratio. *p < 0.05 compared with each control value (Wilcoxon signed-
ranks test).
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family of metabolites resulting from enzymes posses-
sing COX activity [19]. We also showed that non
selective COX inhibitor, indomethacin, can modulate
airway cough reflex sensitivity to inhaled capsaicin [9].
Recently, we conducted another study in patients with
bronchial asthma [20], and showed the role of COX-2
for handling cough reflex sensitivity in asthmatic air-
way with chronic eosinophilic bronchial inflammation.
We, therefore, conducted this study using etodolac
with potent affinity for the COX-2 enzyme over the
COX-1 enzyme, compared with that of celecoxib
[10,11]. Unfortunately, we did not evaluate cough
symptom scores and C2, but we clearly showed the
beneficial effect of two-week treatment with etodolac
for cough reflex sensitivity to inhaled capsaicin. So we
can consider that COX-2 plays some roles in control-
ling cough reflex sensitivity in bronchitic airway with
chronic neutrophilic bronchial inflammation, not only
in asthmatic airway with chronic eosinophilic bronchial
inflammation [20]. The precise mechanisms for modu-
lating role of COX-2 in the pathophysiology of cough
reflex remains unknown since we did not measure ara-
chidonic metabolites in this study. Possible mechanism
is that decreased sputum production caused by COX-2
inhibition may affect our result as shown in previous
study [5]. Recently, Kamei and their colleagues [21]
reported the effect of COX-2 inhibition in cough reflex
sensitivity in guinea pigs and suggested that the inhibi-
tion of substance P release might result in the regula-
tion of endogenous prostaglandins by COX-2 inhibitor
on the capsaicin-sensitive sensory C-fibers. Therefore
we can consider that COX-2, generated in chronic
bronchitic airway known as neutrophilic inflammation
[2-5,17], modulates airway cough reflex sensitivity
through similar mechanisms. Another crucial problem
in clinical practice remains about the cardiovascular
risks of rofecoxib, celecoxib and valdecoxib in the pla-
cebo-controlled trials [22,23], however succeeding
study did not found an elevated cardiovascular risk
with etodolac [24]. Therefore we hope that adverse
reactions in long-term should be clarified in future
studies.
Conclusions
In conclusion, the present study clearly showed that two
week treatment with a potent COX-2 inhibitor, etodo-
lac, attenuated cough reflex sensitivity to inhaled capsai-
cin in patients with sinobronchial syndrome. This is the
f i r s tr e p o r ti n d i c a t i n gt h emodulating role of COX-2 in
airway cough reflex sensitivity of bronchitic airway
known as chronic neutrophilic inflammation. Further
studies are required for elucidating the inflammatory
process in bronchitic airways succeeding COX-2
induction.
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